Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
View Patent ↗The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, pre-term labor, and/or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.
1. A method for determining the presence of intra-uterine infection in a pregnant female mammalian subject comprising: (a) testing in a sample of cervical-vaginal fluid obtained from said subject the abundance of fatty acid-binding protein, epidermal, and one or more proteins selected from the group consisting of haptoglobin precursor; alpha-1-acid glycoprotein, and insulin-like growth factor binding protein relative to the abundance in normal cervical fluid or cervical fluid known to be indicative of intra-uterine infection; and (b) concluding that intra-uterine infection is present if said abundance shows a statistically significant difference relative to abundance in said normal cervical fluid, or does not show a statistically significant difference relative to abundance in said cervical fluid known to be indicative of intra-uterine infection.
2. The method of claim 1 wherein said mammalian subject is human.
3. The method of claim 2 comprising testing the abundance of fatty acid-binding protein, epidermal, and at least two of said proteins.
4. The method of claim 2 comprising testing the abundance of fatty acid-binding protein, epidermal, and at least three of said proteins.
5. The method of claim 2 further comprising testing the abundance of one or more additional proteins selected from the group consisting of profilin-1; serum albumin precursor; calgranulin B; and squamous cell carcinoma antigen 1.
6. The method of claim 2 or claim 5 further comprising testing the abundance of one or more additional proteins selected from the group consisting of alpha-1-antitrypsin precursor; fibronectin precursor; Annexin A2; Vitamin-D binding protein precursor.
7. The method of claim 6 further comprising testing the abundance of one or more additional proteins selected from the group consisting of cystatin A; mucin-5B precursor; small proline-rich protein 3; lysozyme C precursor; and serotransferrin precursor (P02787).
8. The method of claim 1 or claim 5 further comprising testing the abundance of one or more additional proteins selected from the group consisting of cystatin; mucin-5B precursor; small proline-rich protein 3; lysozyme C precursor; and serotransferrin precursor (P02787).
9. The method of claim 2 wherein said abundance is determined by an immunoassay.